Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma.
Anna Wolska-WasherPiotr SmolewskiTadeusz RobakPublished in: Expert opinion on pharmacotherapy (2021)
PTCLs have proved difficult to treat and investigate because of their rarity. Studies of aggressive lymphoma, including a small proportion of T-cell lymphomas, found that any benefit from intensified traditional chemotherapy in patients with PTCL is accompanied by increased toxicity. However, the management of PTCL is beginning to change dramatically, thanks to the use of more sophisticated agents targeting the mechanisms of disease development.